The hearing aid group expects sales growth of 5–8 % in its fiscal year, which runs from April to March.
No actionable change — this is a financial performance report with no direct implications for clinical practice.
Sonova's continued growth signals a healthy and expanding global hearing aid market, which may influence competitive pricing, product availability, and investment in hearing care innovation.
- 01Sonova exceeded its earnings guidance for the most recent fiscal period.
- 02The company projects 5–8% sales growth for fiscal year 2026/27 (April–March).
- 03Reported by MedWatch, an independent trade publication — not a Sonova press release.
- 04Growth outlook suggests sustained consumer demand for hearing devices.
- 05No specific product launches, clinical data, or practice-change information included.
Sonova exceeded its earnings guidance for the reported fiscal period.
press releaseunclearSonova projects 5–8% sales growth for fiscal year 2026/27.
quotepartially supported